Table of contents
Volume 101, Issue 10
Published online 10 November 2009 (1651-1806)
Clinical Studies |
Translational Therapeutics |
Molecular Diagnostics |
Genetics and Genomics |
Corrigenda
Minireview
Preclinical mouse models for BRCA1-associated breast cancer FREE
R M Drost and J Jonkers
Br J Cancer 101: 1651-1657; advance online publication, September 29, 2009; doi:10.1038/sj.bjc.6605350
Clinical Studies
A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer
C Yoo, J Y Hwang, J-E Kim, T W Kim, J S Lee, D H Park, S S Lee, D W Seo, S K Lee, M-H Kim, D J Han, S C Kim and J-L Lee
Br J Cancer 101: 1658-1663; advance online publication, October 13, 2009; doi:10.1038/sj.bjc.6605374
Abnormal expression of TRIB3 in colorectal cancer: a novel marker for prognosis
N Miyoshi, H Ishii, K Mimori, Y Takatsuno, H Kim, H Hirose, M Sekimoto, Y Doki and M Mori
Br J Cancer 101: 1664-1670; doi:10.1038/sj.bjc.6605361
Colonoscopic surveillance improves survival after colorectal cancer diagnosis in inflammatory bowel disease
M W M D Lutgens, B Oldenburg, P D Siersema, A A van Bodegraven, G Dijkstra, D W Hommes, D J de Jong, P C F Stokkers, C J van der Woude and F P Vleggaar On behalf of the Initiative on Crohn and Colitis (ICC)
Br J Cancer 101: 1671-1675; advance online publication, October 13, 2009; doi:10.1038/sj.bjc.6605359
Lapatinib monotherapy in patients with relapsed, advanced, or metastatic breast cancer: efficacy, safety, and biomarker results from Japanese patients phase II studies FREE
M Toi, H Iwata, Y Fujiwara, Y Ito, S Nakamura, Y Tokuda, T Taguchi, Y Rai, K Aogi, T Arai, J Watanabe, T Wakamatsu, K Katsura, C E Ellis, R C Gagnon, K E Allen, Y Sasaki and S Takashima
Br J Cancer 101: 1676-1682; advance online publication, October 20, 2009; doi:10.1038/sj.bjc.6605343
Translational Therapeutics
Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice
S Ganai, R B Arenas and N S Forbes
Br J Cancer 101: 1683-1691; advance online publication, October 27, 2009; doi:10.1038/sj.bjc.6605403
Activation and clinical significance of the unfolded protein response in breast cancer FREE
P Scriven, S Coulson, R Haines, S Balasubramanian, S Cross and L Wyld
Br J Cancer 101: 1692-1698; advance online publication, October 27, 2009; doi:10.1038/sj.bjc.6605365
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells FREE
G E Konecny, R Glas, J Dering, K Manivong, J Qi, R S Finn, G R Yang, K-L Hong, C Ginther, B Winterhoff, G Gao, J Brugge and D J Slamon
Br J Cancer 101: 1699-1708; advance online publication, October 27, 2009; doi:10.1038/sj.bjc.6605381
Clinical importance of B7-H3 expression in human pancreatic cancer
I Yamato, M Sho, T Nomi, T Akahori, K Shimada, K Hotta, H Kanehiro, N Konishi, H Yagita and Y Nakajima
Br J Cancer 101: 1709-1716; advance online publication, October 20, 2009; doi:10.1038/sj.bjc.6605375
Molecular Diagnostics
Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors FREE
R Kumar, M-C Crouthamel, D H Rominger, R R Gontarek, P J Tummino, R A Levin and A G King
Br J Cancer 101: 1717-1723; advance online publication, October 20, 2009; doi:10.1038/sj.bjc.6605366
Abstract | Full Text | PDF | Supplementary information
Detection of BRAF mutations in the tumour and serum of patients enrolled in the AZD6244 (ARRY-142886) advanced melanoma phase II study FREE
R E Board, G Ellison, M C M Orr, K R Kemsley, G McWalter, L Y Blockley, S P Dearden, C Morris, M Ranson, M V Cantarini, C Dive and A Hughes
Br J Cancer 101: 1724-1730; advance online publication, October 27, 2009; doi:10.1038/sj.bjc.6605371
Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells
T Terakawa, H Miyake, J Furukawa, S L Ettinger, M E Gleave and M Fujisawa
Br J Cancer 101: 1731-1739; advance online publication, October 20, 2009; doi:10.1038/sj.bjc.6605358
Chronic bacterial inflammation induces prostatic intraepithelial neoplasia in mouse prostate
J E Elkahwaji, R J Hauke and C M Brawner
Br J Cancer 101: 1740-1748; advance online publication, October 20, 2009; doi:10.1038/sj.bjc.6605370
Expression of delta-like ligand 4 (Dll4) and markers of hypoxia in colon cancer FREE
A M Jubb, H Turley, H C Moeller, G Steers, C Han, J-L Li, R Leek, E Y Tan, B Singh, N J Mortensen, I Noguera-Troise, F Pezzella, K C Gatter, G Thurston, S B Fox and A L Harris
Br J Cancer 101: 1749-1757; advance online publication, October 20, 2009; doi:10.1038/sj.bjc.6605368
Humanised IgG1 antibody variants targeting membrane-bound carcinoembryonic antigen by antibody-dependent cellular cytotoxicity and phagocytosis
S Q Ashraf, P Umana, E Mössner, T Ntouroupi, P Brünker, C Schmidt, J L Wilding, N J Mortensen and W F Bodmer
Br J Cancer 101: 1758-1768; doi:10.1038/sj.bjc.6605355
Hypoxia, Snail and incomplete epithelial–mesenchymal transition in breast cancer
K Lundgren, B Nordenskjöld and G Landberg
Br J Cancer 101: 1769-1781; advance online publication, October 20, 2009; doi:10.1038/sj.bjc.6605369
Genetics and Genomics
Gene expression profiling associated with the progression to poorly differentiated thyroid carcinomas FREE
J M Pita, A Banito, B M Cavaco and V Leite
Br J Cancer 101: 1782-1791; advance online publication, October 6, 2009; doi:10.1038/sj.bjc.6605340
Familial association of pancreatic cancer with other malignancies in Swedish families
E Hiripi, J Lorenzo Bermejo, X Li, J Sundquist and K Hemminki
Br J Cancer 101: 1792-1797; advance online publication, October 13, 2009; doi:10.1038/sj.bjc.6605363
Gene silencing of HPV16 E6/E7 induced by promoter-targeting siRNA in SiHa cells
D Hong, W Lu, F Ye, Y Hu and X Xie
Br J Cancer 101: 1798-1804; advance online publication, October 13, 2009; doi:10.1038/sj.bjc.6605344
Corrigenda
Validating genetic risk associations for ovarian cancer through the International Ovarian Cancer Association Consortium FREE
C L Pearce, A M Near, D J Van Den Berg, S J Ramus, A Gentry-Maharaj, U Menon, S A Gayther, A R Anderson, C K Edlund, A H Wu, X Chen, J Beesley, P M Webb, S K Holt, C Chen, J A Doherty, M A Rossing, A S Whittemore, V McGuire, R A DiCioccio, M T Goodman, G Lurie, M E Carney, L R Wilkens, R B Ness, K B Moysich, R Edwards, E Jennison, S K Kjaer, E Hogdall, C K Hogdall, E L Goode, T A Sellers, R A Vierkant, J M Cunningham, J M Schildkraut, A Berchuck, P G Moorman, E S Iversen, D W Cramer, K L Terry, A F Vitonis, L Titus-Ernstoff, H Song, P D P Pharoah, A B Spurdle, H Anton-Culver, A Ziogas, W Brewster, V Galitovskiy and G Chenevix-Trench Australian Cancer Study (Ovarian Cancer) Australian Ovarian Cancer Study Group on behalf of the Ovarian Cancer Association Consortium
Br J Cancer 101: 1805; doi:10.1038/sj.bjc.6605431
BRCA1 tumours correlate with a HIF-1
phenotype and have a poor prognosis through modulation of hydroxylase enzyme profile expression FREE
M Yan, M Rayoo, E A Takano, KConFab Investigators and S B Fox
Br J Cancer 101: 1806; doi:10.1038/sj.bjc.6605430
The published online date indicates the date that the issue is published online and is the first official publication date of the issue. Each print issue of BJC is published one week after it has been published online.
